Arsenic Trioxide

This is a specific type of arsenic, often used in medicine to treat certain types of leukemia. It's a chemical compound called As2O3.

Brand names:Trisenox
Medication

What people taking Arsenic Trioxide report

Every report comes from a Lived member, sent anonymously.

Have you tried Arsenic Trioxide for Acute Promyelocytic Leukemia?

NameHow it went

About Arsenic Trioxide

What It's For

Arsenic trioxide, sold under the brand name Trisenox and also available as a generic, is an intravenous cancer medicine used for one specific blood cancer: acute promyelocytic leukemia, or APL. APL is a fast-moving form of acute myeloid leukemia in which immature white blood cells called promyelocytes build up in the bone marrow and blood instead of maturing into normal cells. It is driven by an exchange of genetic material between chromosomes 15 and 17 that creates an abnormal protein called PML-RARA, and arsenic trioxide is approved only for APL confirmed to carry this change. In the US, it is approved together with tretinoin (also called all-trans retinoic acid, or ATRA, a pill related to vitamin A) as the first treatment for adults with newly diagnosed low-risk APL. Low-risk means the white blood cell count at diagnosis is 10,000 per microliter or lower. It is also approved to bring APL back into remission, and then keep it there, in people whose disease returned after, or did not respond to, treatment with tretinoin and anthracycline chemotherapy (such as idarubicin). For high-risk APL, where the white count at diagnosis is higher, specialists often combine arsenic trioxide and tretinoin with a reduced amount of chemotherapy. That approach is supported by clinical trials but is outside the US label.

How It Works

In APL, the PML-RARA protein jams the program that normally lets young blood cells mature, so leukemia cells pile up at an immature stage. Arsenic trioxide damages and breaks down this abnormal protein, and in laboratory studies it drives APL cells into a form of programmed cell death. With the block removed, leukemia cells either mature or die off, and the bone marrow can recover and make normal blood cells again. Tretinoin targets the same abnormal protein in a different way, which is why the two medicines work well together and why many people with low-risk APL can now be treated without traditional chemotherapy. Researchers do not fully understand every step of how arsenic trioxide works.

Dosage & Administration

Arsenic trioxide is given only by a healthcare team, as a daily infusion into a vein that usually runs over about 2 hours. The infusion can be slowed to as long as 4 hours if reactions such as flushing occur during the drip, and a central line is not required. The dose is calculated from body weight, and the team pauses or lowers it based on heart tracings, blood tests and side effects. Treatment comes in phases. Induction aims to clear leukemia from the bone marrow, with daily doses until remission, for no more than 60 days. Consolidation then aims to eliminate remaining leukemia cells. For newly diagnosed low-risk APL, consolidation is four 8-week cycles, with infusions 5 days a week during the first 4 weeks of each cycle and tretinoin pills taken on a set schedule. For APL that has come back, consolidation is 25 doses spread over up to 5 weeks, starting 3 to 6 weeks after induction ends. When arsenic trioxide is combined with tretinoin, a steroid called prednisone is usually given throughout induction to help prevent differentiation syndrome, a serious reaction described under Interactions & Warnings.

Side Effects

Most people have some side effects. In clinical trials, the most common included nausea, vomiting, diarrhea, abdominal pain, tiredness, fever, chills, headache, cough, shortness of breath, a fast heartbeat, swelling, rash or itching, trouble sleeping, joint pain and tingling in the skin. Fever, breathlessness, swelling or a racing heartbeat can also be early signs of the serious reactions described under Interactions & Warnings, so they should always be reported rather than treated as routine. Blood tests often show low potassium and magnesium, high blood sugar and a rising white blood cell count, which the team manages as part of routine care. Low blood counts are common during induction and raise the risk of infection and bleeding. In the main trial for newly diagnosed APL, prolonged low platelet and white cell counts and infections were less frequent with arsenic trioxide and tretinoin than with tretinoin and chemotherapy. Nerve problems, mostly tingling, numbness or pain in the hands and feet, appeared in a small share of people, more often during consolidation, and were usually reversible. Liver effects are frequent. About 4 in 10 people treated with arsenic trioxide and tretinoin for newly diagnosed APL had raised liver tests, which settled when treatment was paused. In one long-term follow-up, about 4 in 10 people had fatty liver and about 1 in 7 had mild liver dysfunction a median of 7 years after treatment. Triglycerides and cholesterol can also rise. Three less common but serious reactions have specific warning signs and are covered under Interactions & Warnings.

Interactions & Warnings

Arsenic trioxide carries an FDA boxed warning, the agency's most prominent kind, for three serious problems. Each can be treated when caught early, so patients and caregivers are asked to report the warning signs to the treatment team immediately, day or night. Outside the hospital, a seizure, fainting without quick recovery, or being very hard to wake needs emergency services (911). Differentiation syndrome occurred in about 16 to 23 of every 100 people treated for APL in trials and can be life-threatening. It can start as early as the first day of treatment or as late as the second month of induction. Signs include fever, sudden weight gain or swelling, dizziness or lightheadedness, and labored breathing. The team treats it with high-dose steroids and pauses arsenic trioxide. Arsenic trioxide can lengthen the QT interval, the time on an electrocardiogram (ECG) that the heart's lower chambers take to fire and electrically reset with each beat. A markedly long QT can set off a dangerous rhythm called torsade de pointes, and the drug can also cause complete heart block, in which signals stop passing from the upper to the lower chambers. Fainting or a racing or irregular heartbeat needs immediate attention. The team checks an ECG before starting and at least weekly, and keeps potassium and magnesium in a safe range because low levels raise the risk. If the QT lengthens past a set safety limit, treatment is paused until it returns to normal and then restarted at a lower dose. The drug is not given to people who already have a prolonged QT or a dangerous ventricular rhythm. Serious encephalopathy, a disturbance of brain function, has occurred, including Wernicke's encephalopathy, a neurologic emergency linked to a shortage of thiamine (vitamin B1). Signs include confusion, unusual drowsiness or reduced alertness, seizures, new memory or thinking problems, unsteady walking, and vision changes or abnormal eye movements. People at higher risk of low thiamine, including those with heavy alcohol use, poor nutrition or poor absorption of nutrients, or who take the diuretic furosemide, may be tested and given thiamine by injection. Because of the heart rhythm risk, the care team needs a full list of medicines and supplements. Other drugs that lengthen the QT interval, such as certain antibiotics (erythromycin, moxifloxacin), heart rhythm medicines (amiodarone, sotalol) and some antipsychotics (ziprasidone), are stopped or switched where possible, with more frequent ECGs if they cannot be. Medicines that lower potassium or magnesium, such as diuretics (water pills) and the antifungal amphotericin B, add to the risk, and other medicines that can strain the liver, such as high doses of acetaminophen (Tylenol), add to the liver risk. Arsenic trioxide can harm a developing baby, so a pregnancy test is done before starting. Women who could become pregnant should use effective contraception during treatment and for 6 months after the last dose, and men with a partner who could become pregnant should do so during treatment and for 3 months after. Breastfeeding should stop during treatment and for 2 weeks after the last dose. The drug may reduce male fertility. Arsenic trioxide is a known cause of cancer in humans, so follow-up includes watching for new cancers. It should not be used by anyone allergic to arsenic.

What to Expect

For most people with newly diagnosed APL, arsenic trioxide is part of a treatment with a very high chance of cure. In the trial behind its US approval for low-risk APL, 94 of every 100 people treated with arsenic trioxide and tretinoin were alive without treatment failure or relapse at 2 years, compared with 82 of every 100 treated with tretinoin and chemotherapy. Overall survival at 2 years was 99% versus 91%, and later studies have confirmed the advantage. In APL that had come back, 70% of people in the main trial reached complete remission, and clearing the bone marrow took a median of about 6 weeks. The first weeks are the most demanding and carry the most risk. Most deaths that still occur in APL happen before or during induction, largely from bleeding caused by the leukemia itself, which is why care is so closely watched at the start. Expect blood counts, clotting tests and chemistry several times a week, liver tests at least twice a week, regular ECGs, and frequent potassium and magnesium replacement. Doses are often paused and restarted at a lower level because of liver test changes, QT lengthening or differentiation syndrome. This is common and does not by itself mean treatment is failing. During consolidation, checks usually drop to about once a week. People treated with arsenic trioxide and tretinoin generally do not need maintenance therapy afterward, because relapse after consolidation has been rare. A sensitive molecular test for PML-RARA at the end of consolidation checks for any remaining leukemia, and people with high-risk APL usually repeat it about every three months for 2 to 3 years. Longer-term follow-up also covers liver health and watching for new cancers.

Questions to Ask Your Doctor

  1. 1.Is my APL low-risk or high-risk, and does that change whether chemotherapy is added to arsenic trioxide and tretinoin?
  2. 2.How often will I need infusions, blood tests and ECGs in each phase, and which parts of treatment will happen in the hospital?
  3. 3.Could any of my current medicines or supplements affect my heart rhythm, potassium or liver, and should any be changed?
  4. 4.Who should I call, day or night, if I notice fever, sudden weight gain, trouble breathing, fainting or confusion?
  5. 5.What do I need to know about contraception, fertility and long-term follow-up after treatment ends?

Last reviewed • Oct 2026

Educational content, not medical advice.